Status:
UNKNOWN
Camrelizumab Utilization on Patients With Advanced Liver Cancer
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Advanced Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
Detailed Description
camrelizumab ， a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high affinity for PD-1 ...
Eligibility Criteria
Inclusion
- 18 years old or more;
- For both men and women;
- Patients with advanced liver cancer confirmed by histopathology or cytology; .Volunteer to join the study, sign the informed consent, good compliance, and cooperate with the follow-up.
Exclusion
- A known allergy to the study drug or any of its excipients; Or had a severe allergic reaction to other monoclonal antibodies;
- Patients who are ready for or have previously received an organ or allogeneic bone marrow transplant;
- Pregnant or lactating women;
- According to the judgment of the researcher, the patients should not be included in this study
Key Trial Info
Start Date :
April 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04487704
Start Date
April 7 2020
End Date
January 1 2025
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China, 710061